Studying biomarkers for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial looks at certain blood markers (CCR6 and CCL20) in people with rheumatoid arthritis to see if they can help diagnose or monitor the disease. You may be eligible if you have been diagnosed with RA by a specialist.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have been diagnosed with rheumatoid arthritis by a rheumatologist
- You do not have another autoimmune disease (like lupus or psoriasis)
- You do not have an active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific antibody in the blood that may help diagnose or monitor rheumatoid arthritis (RA). It aims to see if this marker can distinguish RA from other conditions.
This study looks at specific genetic differences and blood levels of immune proteins to see how they relate to rheumatoid arthritis risk and how active the disease is. It may help researchers understand who is more likely to have rheumatoid arthritis and when the condition is more active.
This trial measures levels of a protein called CCL-21 in the blood of people with rheumatoid arthritis, osteoarthritis, and healthy volunteers. The goal is to see if CCL-21 levels relate to disease activity and could help track inflammation.
This study looks at whether a new blood test (anti-PCOLCE) can help diagnose rheumatoid arthritis, especially in people who test negative for standard markers.
This study looks at levels of certain immune system proteins (IL-6, IL-12, IL-15, and IL-23) in the blood of people with rheumatoid arthritis. It aims to understand how these proteins relate to the disease and may help guide future treatments for better outcomes.
This trial looks at cardiovascular risk factors in people with rheumatoid arthritis (RA), comparing those who test positive or negative for certain blood markers. It aims to understand how heart health may differ between these groups.
Hear when a new Rhematoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.